Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
231 0 |
Căutarea după subiecte similare conform CZU |
616.98:578.834-07-085 (1) |
Инфекционные заболевания. Инфекционные лихорадки (586) |
Вирусология (446) |
SM ISO690:2012 MIHALACHE, Nicoleta. Acetylsalicylic acid and SARS-CoV-2 infection. In: Revista de Ştiinţe ale Sănătăţii din Moldova, 2022, nr. 3 An.1(29), p. 59. ISSN 2345-1467. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Revista de Ştiinţe ale Sănătăţii din Moldova | ||||||
Numărul 3 An.1(29) / 2022 / ISSN 2345-1467 | ||||||
|
||||||
CZU: 616.98:578.834-07-085 | ||||||
Pag. 59-59 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Infection with SARS CoV-2 virus increases the risk of developing venous and arterial thromboembolism. The analysis of the pharmacological properties of acetylsalicylic acid (ASA) determined the study of its therapeutic benefits in patients with COVID-19. Objective of the study. The purpose of this study consisted in analyzing the literature with argumentation of the benefit of AAS in patients with SARS CoV-2 infection. Material and Methods. About 50 publications on PubMed and MEDLINE were analyzed and selected to highlight the mechanisms and effects of AAS, responsible for the beneficial effect in COVID-19 patients. Results. Acetylsalicylic acid affects through various mechanisms the development of thrombosis. The antiaggregant effect is achieved by acetylation and irreversible inhibition of COX-1 with decreased production and release of thromboxane A2. At the same time, it can cause general thrombin reduction, inhibition of factor XIII activation, increased permeability and change in fibrin clot structure, intensification of fibrinolysis. Recent studies have estimated that AAS produces an anti-inflammatory effect by inhibiting COX-1 and COX-2 and prostanoid biosynthesis, inhibits leukocyte adhesion and migration, possesses antioxidant effect, and maintains vascular homeostasis. Conclusion. Acetylsalicylic acid, administered in recommended doses as an antiplatelet, can inhibit arterial thromboembolism by irreversible acetylation of macromolecules and proteins involved in platelet aggregation, in the inflammatory process and endothelial dysfunction. |
||||||
Cuvinte-cheie acetylsalicylic acid, COVID-19, thromboembolism, acid acetilsalicilic, COVID-19, tromboembolism |
||||||
|